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ccording to the World Health 
Organization, about 10 million 
people—most of them in low- 
and middle-income countries—die 
needlessly every year because they do 
not have access to existing medicines 
and vaccines [1]. Countless others suffer 
from neglected tropical diseases, such 
as sleeping sickness, lymphatic ﬁ  lariasis, 
and blinding trachoma, for which 
there are still too few safe or effective 
medicines [2]. Drug companies have 
traditionally been reluctant to develop 
drugs for neglected diseases because the 
patients are too poor to pay for them, so 
there is no ﬁ  nancial incentive for drug 
development.
    Comprehensive solutions are thus 
needed to increase both access to 
existing medicines and research on 
neglected diseases. These solutions 
must involve strengthening health-
care systems in poor countries, 
increasing ﬁ  nancial ﬂ  ows for the most 
pressing public health crises, and 
better matching our research and 
development efforts to the needs of 
the poor. The challenges of making 
such wholesale changes are daunting 
[3]. Our organization, Universities 
Allied for Essential Medicines (UAEM) 
(Box 1), a coalition of students and 
faculty at about 25 universities across 
North America, focuses on the role 
of academic research institutions as 
a starting point for closing the access 
and research gaps. To be sure, much 
of the recent progress in global 
health research and awareness can 
be attributed to universities. Yet we 
must go further. As medical students, 
we have a unique ability to “turn the 
spotlight inward” by calling attention to 
our universities’ responsibilities when it 
comes to essential medicines.
  Why  Universities? 
    University research is vital to the 
development of new medicines; total 
biomedical research expenditures at 
universities were US$19.6 billion in 
2002 [4,5]. Meanwhile, the principles 
that guide universities—creating 
and disseminating knowledge for 
public beneﬁ  t—are well aligned 
with the goal of improving access to 
medicines globally. In addition, many 
universities have ofﬁ  ces responsible 
for transferring academic innovations 
(those arising from university research) 
to the commercial sector. Such 
transfer allows these innovations to 
be further developed and marketed 
so that they can beneﬁ  t the public; 
universities rarely have the resources to 
do such development and marketing 
themselves. University technology 
transfer ofﬁ  ces aim to embody the 
same guiding principles as those of 
the university itself. For example, 
the Center for Technology Transfer 
at the University of Pennsylvania 
explicitly states that its chief objective 
is to “commercialize Penn research 
discoveries for the public good” (see 
http:⁄⁄www.ctt.upenn.edu/).
    In most instances, the transfer of 
an innovation from a university to a 
for-proﬁ  t company means that the 
university relinquishes control over 
the subsequent development and 
marketing of a medicine. This raises 
the possibility that the company will 
put the medicine out of reach of poor 
patients, either by charging prices that 
poor patients cannot afford or through 
legal maneuvers that otherwise restrict 
access in poor countries. However, 
two recent cases demonstrate that 
universities can inﬂ  uence access to 
such medicines. 
    First, in 2001, the humanitarian 
organization Médecins Sans Frontières 
sought the permission of Yale 
University to use a generic version of 
Zerit (stavudine), an antiretroviral 
drug for HIV infection, to treat South 
African patients. Médecins Sans 
Frontières made this request because 
it had gathered evidence that generic 
stavudine could be purchased for a 
fraction of the cost of the expensive 
branded version available in South 
Africa; the cost savings would permit 
an expansion in the number of 
patients who could be treated for 
HIV. Yale University owned the patent 
for stavudine, but the university had 
granted an exclusive license that 
conferred intellectual property rights 
for the medicine to the drug company 
Bristol-Myers Squibb (New York, New 
York, United States of America). The 
request from Médecins Sans Frontières 
prompted global attention and intense 
discussions between the university and 
Bristol-Myers Squibb [6]. The result 
was the ﬁ  rst patent concession on 
an HIV drug—that is, Bristol-Myers 
Squibb allowed generic stavudine 
to be bought and sold within South 
Africa—and a 30-fold reduction in the 
price of the patented drug in South 
Africa. The impact of this intervention 
from Médecins Sans Frontières, and 
from Yale’s negotiations with the drug 
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company, was indisputable. Rapid 
expansion of HIV-treatment programs 
in sub-Saharan Africa would not have 
been possible without the widespread 
availability of generic stavudine, a 
treatment recommended by the World 
Health Organization as ﬁ  rst-line 
therapy for HIV/AIDS [7].
    A second example further 
demonstrates the leverage universities 
can have in improving access to 
medicines. Scientists at Emory 
University (Atlanta, Georgia, United 
States of America) had conducted 
research that contributed to the 
development of the antiretrovirals, 
Emtriva (emtricitabine) and Truvada 
(emtricitabine and tenofovir). 
These discoveries were transferred 
to industry through an intellectual 
property agreement that stipulated 
that the university would receive royalty 
payments for any drugs developed from 
the Emory research. Last year, in a 
deal with Gilead Sciences (Foster City, 
California, United States of America) 
and Royalty Pharma (New York City, 
New York, United States of America), 
Emory sold its rights to those royalties 
for a lump sum payment of US$525 
million [8].
    The magnitude of the deal, which 
was the largest-ever transaction of 
its kind for an academic institution, 
caught the attention of student activists 
at Emory, who investigated Gilead’s 
provisions for access to Emtriva and 
Truvada in poor countries and found 
them lacking [9]. Emory students are 
currently engaged in discussions with 
the university administration about 
Gilead’s access practices, armed with a 
straightforward but cogent argument: 
Emory could have received the same 
royalty payment while advocating for 
greater access to Emtriva and Truvada 
for patients in poor countries. That 
is, expanding access does not require 
that universities sacriﬁ  ce their bottom 
line. The reason for this is simple: the 
patients who aren’t currently able to 
afford the drugs they so desperately 
need do not factor into either Gilead’s 
revenue or (by extension) Emory’s 
royalties.
    Closing the Access and Research 
Gaps: Policy Proposals for 
Universities
    The case of Emory and the two 
medicines Emtriva and Truvada 
highlights the difﬁ  culty of crafting 
retrospective solutions to problems 
that should have been foreseen. Ideas 
on how to prevent similar situations 
from arising in the future have been 
circulating in academic and policy 
circles over the past two years. For 
instance, in 2005 the American 
Academy of Arts and Sciences 
(Cambridge, Massachusetts, United 
States of America) published a report 
exploring how to license university 
discoveries to drug companies in a way 
that still ensures that the drugs can be 
accessed for humanitarian uses [10]. 
The report argued that humanitarian 
licensing practices would involve 
“a provision in a license whereby 
inventors and technology suppliers 
protect in advance the possibility of 
sharing their proprietary technology 
with third parties for the beneﬁ  t of 
people in need.” The Association 
of University Technology Managers 
(Northbrook, Illinois, United States 
of America) has convened a group 
known as Technology Managers for 
Global Health to look at how university 
research can be optimally exploited 
to advance global health outcomes 
(http:⁄⁄www.tmgh.org). Our own 
organization, UAEM, has drafted 
recommendations that we advocate 
for individual institutions through our 
university-based chapters [11].
    UAEM proposes that universities 
make changes in both their principles 
and policies in order to improve access 
to medicines in poor countries. We 
recommend that universities adopt 
an ofﬁ  cial resolution that improving 
global human welfare is the most 
important goal of university technology 
transfer. To satisfy this principle, we put 
forward two speciﬁ  c policy proposals: 
(1) universities should adopt licensing 
provisions that facilitate access to 
their health-related innovations in 
poor countries, and (2) universities 
should promote research on neglected 
tropical diseases and ﬁ  nd ways to work 
with nontraditional partners (such as 
developing-world research institutions 
and public–private partnerships) that 
seek to develop medicines for these 
diseases.
    We advocate a set of humanitarian 
licensing provisions known as 
“equitable access licensing,” which is 
designed to do a number of things 
that traditional university licenses 
typically do not do. For example, 
under the Equitable Access License 
   Who  We  Are
      •  UAEM is a coalition of students 
and faculty at about 25 research 
universities across North America.
    •  Our goal is to improve access to 
medicines in poor countries through 
university action. 
   What  We  Do
      •  Our activities take place at both the 
chapter level and the international 
level.
    •  At the chapter level, we petition for 
changes in the policies and practices 
at the universities we attend. For 
example, at the University of California 
Berkeley, administrators announced 
a Socially Responsible Licensing 
Initiative (http://ipira.berkeley.edu/
docs/sociallyresponsible.pdf) that 
arose in part through discussions with 
the Berkeley UAEM chapter.
    •  At the international level, we convene 
groups of students—in consultation 
with faculty members and other 
experts—to determine how best to 
improve access to medicines in poor 
countries through research and policy 
analysis. For example, a consensus 
UAEM Policy Statement was released 
in October 2005 after a meeting at 
Georgetown University (Washington, 
D. C., United States of America) that 
brought together more than 75 
students representing 28 universities 
(see http://www.essentialmedicine.
org/Oct2005PolicyStatement.pdf).
      How You Can Get Involved
      •  Join UAEM through our Web site 
(http://www.essentialmedicine.org).
    •  Figure out what steps your university 
currently takes to ensure access to 
its innovations in poor countries by 
talking to faculty members, technology 
transfer ofﬁ  cers, and administrators 
who set the university research 
agenda.
    •  Learn more about the access and 
research gaps through organizations 
such as Médecins Sans Frontières 
(http://www.accessmed-msf.org) and 
build awareness on your own campus. 
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(EAL), when certain conditions in the 
license are met (e.g., when a generic 
pharmaceutical company in a poor 
country notiﬁ  es the university that a key 
medicine is overpriced there), patent 
barriers are lifted. Under the EAL, 
the intellectual property required to 
make that product is open to anyone 
that wants to use it to increase access 
in poor countries. And so a generic 
pharmaceutical company wanting to 
produce a medicine in a poor country 
won’t get sued for doing so, as long as 
the conditions that trigger the license 
are met. 
    Beyond humanitarian licensing, we 
advocate the institution of policies to 
promote neglected-disease research. 
Speciﬁ  cally, we recommend that the 
universities facilitate participation 
in innovative research activities such 
as public–private partnerships (in 
which the public sector teams up 
with the commercial sector). We also 
recommend that universities promote 
projects that hold potential for 
neglected-disease drug development 
[12]. Such promotion includes 
removing any barriers that prevent 
university scientists from accepting 
research funding from public–private 
partnerships, proactively monitoring 
university innovations for potential 
neglected-disease applicability, and 
ensuring that university intellectual 
property does not serve as an 
impediment for scientists working 
on neglected diseases, either within 
universities or elsewhere. Full details 
of both the EAL and our neglected-
disease policies have been laid out 
elsewhere [13].
  Addressing  Counterarguments
    The unique appeal of an EAL is that it 
promotes true generic competition in 
poor countries. We anticipate, however, 
that the feasibility of our proposal will 
raise a number of doubts, some of 
which we attempt to address here.
    First, it is important to note that for 
any given product, a pharmaceutical 
company’s bottom line would remain 
relatively intact. Equitable Access 
Licensing works by dividing the world 
pharmaceutical market between rich 
and poor countries. Consider, for 
example, any university innovation 
that has been developed into a drug. 
That drug can remain under patent 
protection in high-income countries, 
where the pharmaceutical industry 
earns the vast majority of its revenue. 
Generic competition is allowed only in 
markets where there is little access—
and, therefore, little revenue—in the 
ﬁ  rst place.
    Licensees may express disquiet about 
cheaper generic products overcoming 
regulatory (customs) barriers and 
entering high-income markets illegally. 
However, there is no empirical 
evidence of any substantial ﬂ  ows of 
medicine from poorer countries to 
high-income countries [14]. Insofar 
as such diversion is a concern, EAL 
signatories can address it in the 
same manner that the World Trade 
Organization has—by requiring the 
use of different packaging, pill color, 
and pill shape in different countries 
to facilitate the identiﬁ  cation of illegal 
imports [15].
    Another concern universities may 
have is whether the EAL is ﬁ  nancially 
viable for universities. This concern is 
not justiﬁ  ed, because pharmaceutical 
companies would not lose a signiﬁ  cant 
amount of revenue as a result of the 
EAL, and any decrease in licensing 
revenue at a given university would 
be vanishingly small. The fact that 
licensing revenues typically account 
for about 4% of university research 
funds underscores the point that 
universities would not suffer ill effects 
from implementing Equitable Access 
Licensing [16].
    Finally, aside from any intangible 
beneﬁ  ts research institutions 
might derive from being leaders 
in responding to an important 
humanitarian issue, there are reasons 
to believe that pioneering universities 
stand to gain ﬁ  nancially by adopting 
our proposals. Combining access-
oriented licensing policies with an 
augmented neglected-disease research 
agenda can help universities position 
themselves as research centers for 
foundation-sponsored partnerships. 
The burgeoning ﬁ  eld of public–private 
partnerships for global health research 
has attracted over US$1.2 billion in 
funding from sources such as the Gates 
Foundation, the vast majority of which 
is contracted out to research scientists 
[17]. The University of California 
Berkeley (Berkeley, California, United 
States of America) has recently begun 
marketing its “Socially Responsible 
Licensing Initiative” as a way to attract 
some of this nontraditional funding 
and has already signed a handful of 
deals with foundations and other 
nonproﬁ  ts under that licensing rubric 
[18]. In our role as students, UAEM 
members have even loftier aspirations: 
to foment a collective movement 
that ensures that our universities’ 
innovations reach those who need 
them the most.   
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